Samantha Wilkison is a technical specialist and member of the firm’s Chemistry and Life Sciences Team.
Sam works closely with chemical, biotechnology, and pharmaceutical clients to facilitate application drafting, patent prosecution, and IP portfolio management, with an emphasis on:
• CNS pharmaceuticals
• Therapeutic antibodies
• Synthesis of chemical compounds
• Anti-cancer pharmaceuticals
• biological processes and methods
• Mitochondrial regulation
Education:
- Duke University, Ph.D. 2023
- North Carolina Central University, B.S. Pharmaceutical Sciences 2018
Prior Experience
Samantha Wilkison received her Ph.D. from Duke University, where her research focused on the role of axonal mitochondria in regulating myelin and their contribution to the pathogenesis of glaucoma. Prior to obtaining her PhD, Samantha conducted research on the influence of genetic variability on seizure susceptibility and explored the therapeutic mechanisms of an mTOR inhibitor in the treatment of human glioblastoma.
Publications & Presentations
- Wilkison, S. J., Bright, C.L., Vancini, R., Song, D.J., Bomze, H.M., & Cartoni, R. Local Accumulation of Axonal Mitochondria in the Optic Nerve Glial Lamina Precedes Myelination. Frontiers in Neuronatomy 15, (2021)
- Zimmerman, M., Wilkison, S.., Qi, Q., Chen, G., Li, P. Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Gliobastoma Cells – A synergistic effect with Temozolomide. International Journal of Medical Sciences 17 (2020)